Pharmaceutical

FDA grants fast track status to Edgewise’s Duchenne treatment

The US FDA has granted fast track designation to Edgewise Therapeutics’ EDG-5506 aimed at treating Duchenne muscular dystrophy.

Feb 14, 2024 - 18:00
FDA grants fast track status to Edgewise’s Duchenne treatment
The US FDA has granted fast track designation to Edgewise Therapeutics’ EDG-5506 aimed at treating Duchenne muscular dystrophy.
Read the original article

Tags:

Previous Article

Sudo secures additional funds to advance TYK2 inhibitors to clinic

Next Article

BioAge secures $170m for obesity therapeutics development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: An ultrasound device may unlock brain cancer treatment, early study shows

STAT+: An ultrasound device may unlock brain cancer tre...

May 15, 2023

STAT+: Pharmalittle: FDA commish calls U.S. drug prices ‘too high’; FDA staff says Eisai and Biogen’s Alzheimer’s drug has benefits

STAT+: Pharmalittle: FDA commish calls U.S. drug prices...

Jun 8, 2023

STAT+: Scientists use ‘mini-brains’ to study microglia, the brain’s cleanup crew and key players in neurological disease

STAT+: Scientists use ‘mini-brains’ to study microglia,...

May 11, 2023